Catalyst Pharmaceuticals (CPRX) Insider Trading & Ownership $20.10 +0.43 (+2.16%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Catalyst Pharmaceuticals (NASDAQ:CPRX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage10.40%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$13.43M Get CPRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Catalyst Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CPRX Insider Buying and Selling by Quarter Catalyst Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/11/2025Preethi SundaramInsiderSell1,600$26.42$42,272.00 6/10/2025Preethi SundaramInsiderSell2,324$26.41$61,376.84 5/14/2025Gary IngenitoInsiderSell44,000$23.63$1,039,720.00 5/13/2025Gary IngenitoInsiderSell200,000$23.68$4,736,000.00 3/5/2025Gary IngenitoInsiderSell44,904$22.09$991,929.36 3/3/2025Brian ElsberndInsiderSell62,975$22.98$1,447,165.50 12/10/2024Steve MillerInsiderSell50,000$21.93$1,096,500.00 11/27/2024Gary IngenitoInsiderSell12,000$22.72$272,640.00 11/27/2024Molly HarperDirectorSell17,500$22.00$385,000.00 8/21/2024David S TierneyDirectorSell15,000$20.10$301,500.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 8/20/2024Steve MillerInsiderSell150,000$20.35$3,052,500.00 (Data available from 1/1/2013 forward) CPRX Insider Trading Activity - Frequently Asked Questions Who is on Catalyst Pharmaceuticals' Insider Roster? The list of insiders at Catalyst Pharmaceuticals includes Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Molly Harper, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram, Richard J Daly, and Steve Miller. Learn more on insiders at CPRX. What percentage of Catalyst Pharmaceuticals stock is owned by insiders? 10.40% of Catalyst Pharmaceuticals stock is owned by insiders. Learn more on CPRX's insider holdings. Which Catalyst Pharmaceuticals insiders have been selling company stock? The following insiders have sold CPRX shares in the last 24 months: Alicia Grande ($1,396,800.00), Brian Elsbernd ($1,858,165.50), Carmen Jeffrey Del ($785,372.23), David S Tierney ($1,359,500.00), Gary Ingenito ($8,333,089.36), Molly Harper ($471,927.90), Preethi Sundaram ($103,648.84), Richard J Daly ($276,648.31), and Steve Miller ($4,718,600.00). How much insider selling is happening at Catalyst Pharmaceuticals? Insiders have sold a total of 986,558 Catalyst Pharmaceuticals shares in the last 24 months for a total of $19,303,752.14 sold. Catalyst Pharmaceuticals Key ExecutivesMr. Richard John Daly M.B.A. (Age 63)President, CEO & Director Compensation: $68.12kDr. Steven R. Miller Ph.D. (Age 62)Executive VP, COO & Chief Scientific Officer Compensation: $884.7kDr. Gary Ingenito M.D. (Age 68)Ph.D., Chief Medical & Regulatory Officer Compensation: $811.39kMr. Jeffrey Del Carmen (Age 53)Executive VP & Chief Commercial Officer Compensation: $799.82kMr. Michael W. Kalb CPA (Age 53)Executive VP, Treasurer & CFO Ms. Mary ColemanVP & Head of Investor RelationsMr. Brian Elsbernd J.D. (Age 60)Chief Compliance Officer & Chief Legal Officer Compensation: $311.42k1 recent tradesMr. Pete Curry Sr.Vice President of SalesDr. Stanley Iyadurai M.D.Ph.D., Senior Vice President of Medical Affairs & Drug DiscoveryDr. Preethi Sundaram Ph.D. (Age 48)Chief Strategy Officer Compensation: $511.25k More Insider Trading Tools from MarketBeat Related Companies Viatris Insider Transactions BridgeBio Pharma Insider Transactions Verona Pharma PLC American Depositary Share Insider Transactions Blueprint Medicines Insider Transactions Roivant Sciences Insider Transactions Grifols Insider Transactions Elanco Animal Health Insider Transactions Revolution Medicines Insider Transactions Rhythm Pharmaceuticals Insider Transactions Nuvalent Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:CPRX) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access